ATN 081: Treatment and De-Intesification and Residual HIV-1 in Adolescents and Young Adults, A Sub-study of ATN 061 and ATN 071
ID Number 00-0667-00029Principal Investigator(s)
John B. Steever
Department(s) or Division(s)
This study is a laboratory based sub-study of ATN 061 and ATN 071 to examine the effect of early treatment (HAART at CD4+ T Cells > 350 cells/mm3) followed by treatment de-intensification on steady-state frequencies of replication-competent CD4+ T cell HIV-1 reservoirs or cell-associated infectivity (CAI) and persistent low-level viremia (LLV). The extent of LLV, and their subsequent effects on the long-term successful control of HIV-1 replication will be examined among HIV-1 infected adolescents and young adults initiating HAART at CD4+ T cells > 350 cells/mm3 (early therapy) and undergoing a switch to maintenance therapy with atazanavir/ritonavir (ATV/r) monotherapy.
The primary mission of the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Intervention is to conduct research, both independently and in collaboration with existing research networks such as the HIV Prevention Trials Network (HPTN), HIV Vaccine Trials Network (HVTN), and the Pediatric and Adult AIDS Clinical Trials Groups (PACTG, AACTG), the Community Programs for Clinical Research on AIDS (CPCRA), and others, on promising behavioral, microbicidal, prophylactic, therapeutic, and vaccine modalities in HIV-infected and HIV-at-risk adolescents, ages 12 through 24 years.
Recruiting Patients: Yes